These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 27639777)

  • 1. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
    North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
    J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.
    Thomas DE; Kaimakliotis HZ; Rice KR; Pereira JA; Johnston P; Moore ML; Reed A; Cregar DM; Franklin C; Loman RL; Koch MO; Bihrle R; Foster RS; Masterson TA; Gardner TA; Sundaram CP; Powell CR; Beck SDW; Grignon DJ; Cheng L; Albany C; Hahn NM
    Clin Genitourin Cancer; 2017 Aug; 15(4):479-486. PubMed ID: 28040424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results.
    Scattoni V; Bolognesi A; Cozzarini C; Francesca F; Grasso M; Galli L; Torelli T; Campo B; Villa E; Rigatti P
    Tumori; 1996; 82(5):463-9. PubMed ID: 9063525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
    Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
    J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.
    Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H
    Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
    Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.
    Soloway MS; Lopez AE; Patel J; Lu Y
    Cancer; 1994 Apr; 73(7):1926-31. PubMed ID: 8137219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours.
    Sengeløv L; von der Maase H; Lundbeck F; Barlebo H; Colstrup H; Engelholm SA; Krarup T; Madsen EL; Meyhoff HH; Mommsen S; Nielsen OS; Pedersen D; Steven K; Sørensen B
    Acta Oncol; 2002; 41(5):447-56. PubMed ID: 12442921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
    Kim PH; Kent M; Zhao P; Sfakianos JP; Bajorin DF; Bochner BH; Dalbagni G
    World J Urol; 2014 Apr; 32(2):453-9. PubMed ID: 23842986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y
    Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.
    Audenet F; Waingankar N; Ferket BS; Niglio SA; Marqueen KE; Sfakianos JP; Galsky MD
    J Urol; 2018 Nov; 200(5):996-1004. PubMed ID: 29879397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
    Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
    J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response.
    Hatcher PA; Hahn RG; Richardson RL; Zincke H
    Eur Urol; 1994; 25(3):209-15. PubMed ID: 8200403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose dense MVAC prior to radical cystectomy: a real-world experience.
    Zargar H; Shah JB; van de Putte EEF; Potvin KR; Zargar-Shoshtari K; van Rhijn BW; Daneshmand S; Holzbeierlein JM; Spiess PE; Winquist E; Horenblas S; Dinney C; Black PC; Kassouf W
    World J Urol; 2017 Nov; 35(11):1729-1736. PubMed ID: 28625005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.